What Inocras does

Inocras is a private bioinformatics-led genomic testing company founded in 2020 and headquartered in San Diego, with operational entities in South Korea (Daejeon) and Hong Kong. The company operates a CAP-accredited, CLIA-certified, and ANAB-accredited laboratory and delivers three whole-genome clinical assays: CancerVision (target-enhanced WGS for solid tumor profiling with paired somatic and germline analysis, 600-gene panel at 500× depth, and 2-week turnaround), MRDVision (whole-genome, tumor-informed ctDNA minimal residual disease detection at LOD95 as low as 1 ppm, integrated with Ultima Genomics' ppmSeq technology), and RareVision (30× germline WGS covering 5,000+ rare diseases per ACMG/ClinGen standards). The platform is supported by a research services business providing WGS/WES/WTS, methylation, single-cell, and spatial transcriptomics to biopharma, biobanks, and health tech clients, with named deployments at Samsung Medical Center, Seoul St. Mary's Hospital, the Broad Institute, and 50+ additional research and biopharma institutions.

Underpinning the clinical and research products is a proprietary AI stack centered on DNAChunker, a learnable adaptive tokenization architecture co-developed with KAIST and accepted at ICML 2026, and a Cancer Foundation Model trained on 2,882 whole genomes. These power variant calling, structural variant and copy number detection, mutational signature analysis, and clinical interpretation across the product family. The company has assembled large harmonized whole-genome data assets (8,000+ TCGA tumor-normal whole genomes with the Broad Institute, 1,364-genome breast cancer cohort published in Nature 2025, 10,000+ research WGS) and announced a planned 100,000-patient cancer genome program for 2026.

Inocras generates revenue through per-test clinical fees for CancerVision, MRDVision, and RareVision (patients pay out-of-pocket in the US as these tests are not currently covered by insurance), recurring MRDVision follow-up tests priced at promotional $1,000/test ($4,000 for four), project-based research sequencing and bioinformatics services to biopharma and biobanks, and managed-services biopharma clinical trial partnerships (e.g., Accent Therapeutics' ATX-295 Phase 1/2 study). The company sells through a direct sales team to hospitals, oncologists, and biopharma, supplemented by a self-serve online provider order portal, a direct-to-consumer patient portal at portal.inocras.com, and reseller channels including NDS Corporation for cloud-based deployment into healthcare institutions. Backers include Samsung Ventures, Asan Foundation, Seoul Clinical Laboratories, Ignite Innovations, DSC Investment, Dunamu & Partners, InterVest, Paratus Investment, and Signite, with cumulative disclosed funding of approximately $52.7M across rounds in 2020, 2021, 2022, 2023, and 2024.

Name

Inocras

Legal name

Inocras Inc.

Website

https://inocras.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

Inocras is a San Diego-based bioinformatics company that delivers AI-powered whole-genome clinical testing for cancer (CancerVision), minimal residual disease (MRDVision), and rare diseases (RareVision), serving patients, oncologists, hospitals, and biopharma sponsors from CAP/CLIA-certified labs in the US and South Korea.

Ownership category

akta.pro rank

Product category

Clinical Genomic Diagnostics

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Computer Programming, Data Processing, Etc. (7370), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Whole genome sequencing
• Cancer genomic testing
• Rare disease diagnostics
• Minimal residual disease detection
• Clinical bioinformatics services

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Genomic Testing Services (CancerVision, MRDVision, RareVision): CAP/CLIA-validated whole-genome diagnostic tests billed to patients (out-of-pocket, not currently covered by US insurance) or ordered by providers via online portal. Pricing per test/service, with 2-week turnaround.
2. Research Sequencing & Bioinformatics Services: End-to-end next-generation sequencing (WGS, WES, WTS, methylation, single cell, spatial transcriptomics) plus custom bioinformatics, interpretation, and report generation sold to biopharma, biobanks, research organizations, and health tech firms. Hourly or project-based expert advisory support also offered.
3. Biopharma Partnership / Clinical Trial Support: Co-development and clinical-trial enablement programs (e.g., Accent Therapeutics using CancerVision/MRDVision in Phase 1/2 ATX-295; Samsung Medical Center & Seoul St. Mary's Hospital 1,364-genome breast cancer study) generating project-based and milestone revenue from biopharma sponsors.
4. MRDVision Follow-up Testing (Recurring): Follow-up MRDVision tests in 7–14 day turnaround after initial baseline, creating repeat/recurring per-test revenue from biopharma and clinical customers tracking patient MRD status over time.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

Core offering

Inocras delivers CAP/CLIA-certified whole-genome sequencing clinical diagnostic tests—CancerVision for solid tumor profiling, MRDVision for minimal residual disease detection, and RareVision for rare disease diagnosis—processed in its own San Diego laboratory with a 2-week turnaround. It also offers end-to-end research sequencing and bioinformatics services (WGS, WES, WTS, methylation, single-cell, spatial) and biopharma clinical trial support, all built on a cloud-native AWS HealthOmics platform and proprietary AI including the DNAChunker architecture and Cancer Foundation Model.

Product overview

Inocras delivers a bioinformatics-led whole-genome insights platform organized as a portfolio of three core clinical assays plus research services, all built on shared WGS technology and proprietary AI. The three clinical products are CancerVision (solid tumor profiling), MRDVision (minimal residual disease detection), and RareVision (rare disease diagnosis), each delivered through Inocras's CAP/CLIA-certified laboratory with a 2-week turnaround. MRDVision extends CancerVision by combining it with Ultima Genomics' ppmSeq technology for ultra-sensitive ctDNA monitoring. Underpinning the platform are Inocras's proprietary AI capabilities, notably the DNAChunker learnable tokenization architecture and the Cancer Foundation Model trained on 2,882 whole genomes (developed with KAIST), which together power the variant calling, biomarker prediction, and clinical interpretation pipelines across the product family. End-to-end Research Services (sequencing plus bioinformatics, including NovaSeq X Plus and Ultima UG 100) round out the offering for biopharma, biobanks, and health technology clients.

Differentiator

Problem solved

Functional benefit

Brands

• CancerVision™: Target-enhanced whole-genome sequencing test for solid tumor cancer profiling; paired somatic + germline assay with 99% sensitivity, TMB/MSI/HRD signatures, and clinical trial matching.
• MRDVision™
• RareVision™

Products and services

• CancerVision Target-enhanced whole-genome sequencing test for solid tumor profiling providing 40x tumor / 20x germline coverage with 600+ clinically relevant genes at 500x depth. Delivers 99% sensitivity/positive predictive value (99% SNVs, >98% indels) in a CAP/CLIA-certified assay with 2-week turnaround, including TMB, MSI, HRD, mutational signatures, and clinical trial matching.
• MRDVision Whole-genome, tumor-informed ctDNA test for minimal residual disease detection with LOD95 as low as 1 ppm. Combines CancerVision with Ultima Genomics' ppmSeq technology for a panel-free whole-genome MRD design with 100–1,000x greater sensitivity than existing MRD approaches and 2-week (7–14 day follow-up) turnaround.
• RareVision Whole-genome test for rare disease diagnosis covering genes associated with 5,000+ rare diseases at approximately 30x depth. Identifies 23.6% more rare disease cases vs other genetic testing methods and reports positive, inconclusive, and secondary findings per ACMG/ClinGen guidelines, with genetic counseling support.
• Research Sequencing and Bioinformatics Services End-to-end next-generation sequencing (WGS, WES, WTS, methylation, single cell, spatial transcriptomics) plus custom bioinformatics, interpretation, and report generation on Illumina NovaSeq X Plus and Ultima UG 100 platforms, with hourly or project-based expert advisory support. Sold to biopharma, biobanks, research organizations, and health technology companies.

Quantifiable outcome

• Detected 23.6% more rare disease cases vs other genetic testing methods (sensorineural hearing loss cohort)
• +6 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability8 records

Feature6 records

Partnerships

Twelve partnerships are on record, tiered flagship, core and minor.

• KAIST (Korea Advanced Institute of Science and Technology)flagshipStrategic or Co-development Partner · 22 June 2026Joint research collaboration with KAIST on DNAChunker, a learnable adaptive tokenization approach for DNA language models. The resulting paper was accepted for publication at ICML 2026. The DNAChunker model achieves state-of-the-art performance matching leading 1.2 billion-parameter DNA language models while using only 172 million parameters (>7x smaller). Previously, Inocras and KAIST also collaborated on the Cancer Foundation Model trained on 2,882 whole genomes (announced Nov 2025).
• Broad Institute of MIT and HarvardflagshipStrategic or Co-development Partner · 18 March 2026Joint research collaboration with the Broad Institute analyzing over 8,000 tumor-normal whole genomes from The Cancer Genome Atlas across more than 30 cancer types, generating more than 250 million harmonized variant calls. Presented at AACR Annual Meeting 2026. The two organizations are jointly introducing the Cancer Genome Nexus initiative to scale the standardized whole-genome framework to larger datasets.
• NDS CorporationflagshipStrategic or Co-development Partner · 12 March 2026Strategic partnership with NDS Corporation, a South Korean IT services provider focused on healthcare data and cloud solutions, to jointly develop and commercialize cloud-based genomic analysis platforms for healthcare institutions. Combines Inocras's clinical interpretation expertise with NDS's cloud infrastructure on AWS HealthOmics; planned expansion into North America.
• Samsung Medical CentercoreStrategic or Co-development Partner · 3 December 2025Research consortium partner with Inocras and Seoul St. Mary's Hospital that published a comprehensive whole-genome breast cancer study in Nature (2025) analyzing 1,364 genomes and clinical data; identified biomarkers linked to treatment responses and prognosis supporting precision oncology.
• Seoul St. Mary's HospitalcoreStrategic or Co-development Partner · 3 December 2025Research consortium partner with Inocras and Samsung Medical Center on the Nature (2025) whole-genome breast cancer study of 1,364 genomes with clinical records.
• Ultima GenomicscoreTechnology or IntegrationTechnology integration partner: Inocras's MRDVision platform merges its CancerVision whole-genome platform with Ultima Genomics' ppmSeq™ technology to achieve parts-per-million level ctDNA sensitivity. Ultima UG 100 sequencing is also used in Inocras's research sequencing services. Featured as a partner logo on the Inocras website.
• Samsung Life InsurancecoreStrategic or Co-development PartnerListed as a partner on Inocras's website; relationship provides commercial channel for whole-genome insights into insurance / health offerings.
• Asan Medical CentercoreStrategic or Co-development PartnerListed as a partner on the Inocras website; academic medical center collaboration supporting clinical research and validation.
• DNAVisitminorChannel Partner/ Reseller/ DistributorListed as a partner on the Inocras website; consumer/channel partner enabling patient access to Inocras's whole-genome tests.
• Guide GeneticsminorStrategic or Co-development PartnerListed as a partner on the Inocras website; collaboration supporting genetic testing / counseling access.
• Seoul Clinical Laboratories (SCL)coreStrategic or Co-development PartnerListed as both an investor and partner on the Inocras website; Korean clinical laboratory collaboration supporting sample handling and clinical reach.
• Massive BiominorGTM or Marketing PartnerListed as a partner on the Inocras website; GTM partner supporting clinical trial enrollment and patient matching services.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Tempus AI: AI-driven precision medicine company offering multi-modal molecular profiling (DNA/RNA), MRD, and biopharma data services. Directly competes with Inocras in AI-led oncology genomics and clinical-trial enablement.
• Guardant Health: Liquid biopsy leader with Guardant360 (tumor profiling) and Reveal MRD. Direct competitor in oncology ctDNA profiling and MRD, where Inocras positions MRDVision with whole-genome panel-free sensitivity.
• Natera: Oncology and reproductive health testing company whose Signatera tumor-informed MRD is the entrenched standard. Overlaps directly with Inocras's MRDVision in MRD use cases across solid tumors.
• Caris Life Sciences: Molecular profiling company offering MI Profile (tumor WES/WTS) and Caris Assure MRD. Closely comparable WGS/WES-based profiling and biopharma services model targeting similar oncologists and pharma customers.
• Personalis: Cancer genomics company with NeXT Personal (tumor-informed, whole-genome MRD) and ImmunoID Next platform. Most direct peer to Inocras's WGS-based tumor profiling and MRD strategy.

Broad incumbents

• Foundation Medicine: Roche subsidiary and pioneer of comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx). Competes head-to-head in solid-tumor profiling with an FDA-approved panel; broader portfolio and deeper payer coverage than Inocras.
• NeoGenomics: Clinical oncology and rare-disease laboratory offering comprehensive tumor profiling and heme malignancies panels. Competes in the hospital/community oncology channel with broader test menus.
• Veracyte: Molecular diagnostics company with oncology (Decipher Prostate, Afirma) and recently expanded MRD/biomarker offerings. Overlaps with Inocras in genomic-based clinical decision support for oncologists.
• Exact Sciences (Genomic Health): Oncology diagnostics leader with Oncotype DX and an emerging MRD franchise (Oncodetect). Comparable in bringing multi-gene and emerging tumor-informed testing into community oncology practice.

Emerging players

• Strand Life Sciences: Bioinformatics and genomics services company serving hospitals, clinicians, and researchers in India and globally. Comparable as a bioinformatics-led, hospital-anchored clinical genomics provider; partial overlap in clinical reporting and rare-disease use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@inocras
• LinkedInlinkedin.com/company/inocras-inc
• Xx.com/inocras
• Facebookfacebook.com/61558077998071

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds8 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inocras